B-hPD-L1/hOX40 mice
| Strain Name |
C57BL/6-Cd274tm1(CD274)Bcgen Tnfrsf4tm1(TNFRSF4)Bcgen/Bcgen
|
Common Name | B-hPD-L1/hOX40 mice |
| Background | C57BL/6 | Catalog number | 120534 |
|
Related Genes |
CD274 (CD274 antigen) TNFRSF4 (tumor necrosis factor receptor superfamily, member 4) |
||
|
NCBI Gene ID |
60533,22163 | ||
Protein expression analysis
Strain specific OX40 and PD-L1 expression analysis in homozygous B-hPD-L1/hOX40 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-L1/hOX40 (H/H) mice stimulated with anti-CD3ε in vivo (7.5 μg/mice), and analyzed by flow cytometry with species-specific anti-OX40 antibody. Mouse OX40 and PD-L1 were exclusively detected in WT mice. Human OX40 and PD-L1 were exclusively detected in homozygous B-hPD-L1/hOX40 but not WT mice.
Combination therapy of PD-L1 Ab and OX40 Ab
Antitumor activity of anti-hOX40 antibody combined with anti-hPD-L1 antibody in B-hPD-L1/hOX40 mice. (A) Anti-hOX40 antibody combined with anti-hPD-L1 antibodies inhibited MC38-hPD-L1 tumor growth in B-hPD-L1/hOX40 mice. Murine colon cancer MC38-hPD-L1 cells (5×105) were subcutaneously implanted into homozygous B-hPD-L1/hOX40 mice (female, 6-7 week-old, n=6). Mice were grouped when tumor volume reached approximately 150±50 mm3, at which time they were treated with anti-hOX40 antibody combined with anti-hPD-L1 antibody with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of anti-hOX40 and anti-hPD-L1 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-L1/hOX40 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hOX40 antibodies and hPD-L1 antibodies. Values are expressed as mean ± SEM.
+86-010-56967680
010-56967601
ir@bbctg.com.cn
Copyright © 2021 Biocytogen. All Rights Reserved
Powered by Fractal-technology